Brief: Novan Announces Positive Preclinical Data In Sb019 Covid-19 Anti-Viral Therapy Program

NVN Liquidation

10/06/2021 13:40

June 10 (Reuters) - Novan Inc  NOVN.O :
    * NOVAN ANNOUNCES POSITIVE PRECLINICAL DATA IN SB019
COVID-19
ANTI-VIRAL THERAPY PROGRAM
    * NOVAN INC - PRELIMINARY TOXICOLOGY AND PHARMACOLOGY STUDY
RESULTS SUGGEST INTRANASAL ADMINISTRATION IS WELL-TOLERATED AND
SAFE
    * NOVAN INC - STATISTICALLY SIGNIFICANT, DOSE-DEPENDENT
REDUCTION
IN AMOUNT OF VIRUS IN LUNG WITH DOSES AS LOW AS 2 MG/ML

Source text for Eikon:  ID:nGNX8thZh3 
Further company coverage:  NOVN.O 

 ((Reuters.Briefs@thomsonreuters.com;))